Dew. re ARDX I have a small position in the Co and my take is as follows .
Co will need $ by EOY to fund their drug for use by dialysis patients ( assuming final P 3 is successful ) ...so they need to find a partner soon , for the IBSC indication , who is willing to make a large upfront payment ...or ...they will do a capital raise and dilute current shareholders.
Finding a partner may be challenging as its not clear to me that their drug has any significant benefit over Linzess which is currently on the market ...sales of $761m in 2018 . There may be some that can't tolerate Lizness but may do better on Tenapanor ( ARDX ) but Lizness obviously has first mover advantage
Thx for you post on public buy outs of Biotech Co's ...I linked some of it to the AMRN board since many there expect AMRN to receive the highest $ BO offer in recent memory ...once the wider indication is approved ( late dec 2019 ). We'll see ..:-)
News 
Market Data 
Discover 
